Clinical Trial Detail

NCT ID NCT02835833
Title Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Alabama at Birmingham
Indications

lung non-small cell carcinoma

ovarian carcinoma

renal cell carcinoma

colorectal adenocarcinoma

cervix carcinoma

Therapies

Bevacizumab + Nintedanib

Age Groups: senior adult

No variant requirements are available.